AMPH vs ZBH: fair value comparison
Amphastar Pharmaceuticals, Inc. and Zimmer Biomet Holdings, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ZBH currently sits closer to the top of our ranking by discount to fair value.
| AMPH | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $25.87 | $89.14 |
| 12-month range | $16.87–$29.40 | $79.58–$103.18 |
| Rank by discount to fair value | #27 of 108 Healthcare | #24 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Fairly Valued |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: AMPH fair value analysis · ZBH fair value analysis